Warther Private Wealth LLC Decreases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Warther Private Wealth LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 93.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,150 shares of the specialty pharmaceutical company’s stock after selling 31,065 shares during the quarter. Warther Private Wealth LLC’s holdings in Jazz Pharmaceuticals were worth $265,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Summit Trail Advisors LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter worth about $539,000. Savant Capital LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $272,000. Thompson Investment Management Inc. grew its stake in Jazz Pharmaceuticals by 8.2% in the 4th quarter. Thompson Investment Management Inc. now owns 7,220 shares of the specialty pharmaceutical company’s stock valued at $889,000 after buying an additional 550 shares in the last quarter. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $464,000. Finally, Bleakley Financial Group LLC lifted its position in shares of Jazz Pharmaceuticals by 52.5% during the fourth quarter. Bleakley Financial Group LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock worth $383,000 after acquiring an additional 1,071 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $177.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 5,053 shares of company stock worth $617,442 over the last ninety days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $129.98 on Wednesday. The business’s 50-day moving average price is $122.56 and its 200-day moving average price is $116.63. The firm has a market capitalization of $7.86 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.